Loading

Annals of Orthopedics and Rheumatology

Therapeutic Response of Patients followed for Systemic Lupus Erythematosus in the Rheumatology Department of the University Hospital of Bogodogo

Short Note | Open Access Volume 9 | Issue 1 |

  • 1. Department of Rheumatology, University Hospital of Bogodogo, Burkina Faso
  • 2. University Joseph KI-ZERBO, Ouagadougou, Burkina Faso
  • 3. Department of Basic and Mixed Sciences, University Joseph KI-ZERBO, Burkina Faso
+ Show More - Show Less
Corresponding Authors
Wendlassida Joelle Stéphanie ZABSONRE/ TIENDREBEOGO, Associate Professor in Rheumatology, Department of Rheumatology, University Hospital of Bogodogo, 09 BP 88 Ouagadougou 09, Burkina Faso, Tel: (226) 79656502
Abstract

Objective: To analyze the therapeutic response of patients followed for systemic lupus erythematosus in the rheumatology department of the university hospital of Bogodogo from January 2006 to December 2020.

Method: This was a cross-sectional and analytical study with retrospective data collection conducted in the rheumatology department of the university hospital of Bogodogo in Burkina Faso, from January 1, 2006 to December 31, 2020. The diagnosis of SLE was based on the existence of at least four of the ACR/EULAR criteria, with quantitative or qualitative evidence of immunopositivity to at least anti-native DNA and anti-Sm autoantibodies.

Results: Hydroxychloroquine was prescribed as background treatment in 27 patients (93.10%). Under treatment, the evolution was marked by clinical remission in 15 patients (55.17%), and a mean SELENA-SLEDAI score of 4.2 ± 3.97 with extremes of 0 to 13 compared to 9.07 ± 6.64 with extremes of 0 to 23 of mean SELENA-SLEDAI score (p=0.001), over one year of follow-up. Immunologically, the mean anti-dsDNA antibody level was 93.08 ± 117.43 IU at diagnosis versus 20.08 ± 13.48 IU at control (p=0.041), with a mean time interval of 5.25 ± 4.01 years with extremes of 0.41 and 15 years.

Conclusion: A clinical improvement and an immunological response were observed under treatment.

Keywords

Therapeutic response, SLE. Burkina Faso

Citation

YAMEOGO NW, ZABSONRE/TIENDREBEOGO WJS, TINNI IA, SAWADOGO S, KABORE F, et al. (2022) Therapeutic Response of Patients followed for Systemic Lupus Erythematosus in the Rheumatology Department of the University Hospital of Bogodogo. Ann Orthop Rheumatol 9(1): 1098

INTRODUCTION

Systemic lupus erythematosus (SLE), is a chronic systemic autoimmune disease with mainly osteoarticular and dermatological expression, associated with the production of multiple autoantibodies, the most characteristic of which are directed against certain components of the nucleus such as native DNA [1]. Epidemiologically, it is the most common connective tissue disease [2]. It is a serious disease with a multifactorial cause involving environmental, hormonal and genetic factors, leading to a dysfunction of the immune system, hormonal and cellular hyperactivity, responsible for the production of numerous autoantibodies and various tissue lesions [1]. Therapeutically, the treatment of SLE is based on synthetic antimalarials, in particular hydroxychloroquine, corticosteroid therapy, nonsteroidal anti-inflammatory drugs, immunosuppressants depending on the severity of the disease, and biotherapy, which has brought a new dimension to the therapeutic management of autoimmune diseases [1]. From an evolutionary point of view, lupus disease evolves spontaneously through successive relapses, interspersed with remissions of varying duration and quality under treatment. The “activity” of the disease is assessed by activity scores, the most important of which are the SLEDAI (Systemic lupus erythematosus disease activity index), and the BILAG (British Isles Lupus Activity Group). These scores are based on the presence or absence of clinical and biological signs, with different weightings according to the severity of the organ damage observed [3]. These scores allow practitioners to define whether the patient is in remission or not. Many studies have been conducted on the evolution of treatment in practice, both clinically and immunologically in Western countries, but very few in Africa, hence the purpose of our study.

PATIENTS AND METHODS

The rheumatology department of the Bogodogo University Hospital in Burkina Faso served as the setting for our study. It was a descriptive cross-sectional and analytical study with retrospective data collection covering the period from January 2006 to December 2020. All patients with a diagnosis of SLE based on the existence of at least 04 ACR/EULAR criteria with quantitative or qualitative evidence of immunopositivity to at least anti-native DNA and anti-Sm autoantibodies were included. Data were entered and analyzed on a microcomputer using SPSS version 2.0 software. Tables and graphs were made with Microsoft Excel 2019 software.

Categorical variables were expressed as frequency. Quantitative variables were expressed as mean and standard deviation or median and interquartile range. Comparison of quantitative variables was performed using a Pearson correlation test. The comparison of qualitative variables was done by calculating the Odd ratio. The risks are defined by an Odd Ratio > 1 if the test is significant. A significance threshold of 0.05 was used.

RESULTS

Twenty-nine (29), patients were included in our study. The mean age of the patients was 32 ± 8.60 years with extremes of 08 and 46 years. 96.55% were female, i.e. a sex ratio of 0.04. The average duration of treatment was 5.25 years ± 4.01 years with extremes of 0.41 and 15 years. The cutaneous and rheumatological manifestations were represented by 44.86% of photosensitivities, 75.86% of lupus skin lesions, 79.31% of arthralgias and 27.59% of arthritides were observed at diagnosis. The average 24-hour proteinuria was 0.93 ± 1.7 g/24h at the time of diagnosis with extremes of 0.01 and 1.85 g/24h. It was positive in 13 patients. Table 1 compares the distribution of patients according to organ involvement at diagnosis and control. Concerning the immunological profile, anti-native DNA and anti-Sm antibodies were positive in 68.97% of patients. The mean value of anti-native DNA antibodies was 93.08 ± 117.43 IU with extremes from 0 to 380 IU at diagnosis versus 20.08 ± 13.38 IU with extremes from 0 to 47 IU at control (p=0.041). Table 2 compares the autoantibody levels of patients at diagnosis and control. Hydroxychloroquine was administered in 93.10% of patients. The mean SELENA-SLEDAI 2 score was 4.62 ± 3.97 with extremes of 2 to 13 compared to 9.07 ± 6.64 with extremes of 0 to 23 mean SELENA-SLEDAI 1 score (p=0.001). Table 3 shows the comparison of the SELENA-SLEDAI 1 and 2 scores. Clinical remission was observed in 55.17% of patients at the time of control.

DISCUSSION

We noted a significant clinical improvement in rheumatological manifestations (P=0.004). Our results were comparable to those of Aouhab in Illinois, USA [4]. This result shows the therapeutic effectiveness of the molecules indicated for the management of SLE [1]. Regarding the renal manifestations, in our sample the renal function was disturbed in 13 patients at diagnosis, with a positive mean 24-hour proteinuria of 0.93 ± 1.7g/24h. Our results are superior to those of Diop in Senegal in whom renal function was disturbed in 8 (11.1%) patients [5]. On the other hand, Shariati-Sarabi in Iran did not note any cases of renal impairment in his sample of 41 patients [6]. The average 24-hour proteinuria at control was 0.44 ± 0.51g/24h. Our result could be explained by the frequency of renal involvement at diagnosis and during the course of SLE as described in the literature [7], or by the existence of a urogenital tract infection that should have been ruled out by a uroculture examination. Hydroxychloroquine was the most commonly administered drug, accounting for 93.10% of cases. In general, in West Africa, the diagnosis of SLE remains difficult because of the clinical polymorphism. However, the disease seems to be benign in the sub-region with a management that remains dominated by corticosteroid therapy and synthetic antimalarials; immunosuppressants and biotherapy being of difficult use and accessibility in our countries [8].

The immunological profile of the patients at the beginning was dominated by anti-DNA and anti-Sm antibodies in 51.72% of patients. Toumin in Ivory Coast also noted immunological disorders in 85.19% of patients [9]. At the immunological control, we noted a significant decrease in the average level of anti-DNA antibodies (P=0.04), under hydroxychloroquine alone or associated with cyclophosphamide or azathioprine) over a mean treatment duration of 5.25 ± 4.01 years. Shariati-Sarabi in Iran and Gheita in Egypt, had also reported a significant decrease in anti-DNA (p<0.001)[6], (P=0.013)[10], respectively under hydroxychloroquine and cyclophosphamide. In our sample, we found two cases of auto-antibody negativation in two patients aged 20 and 08 years at control, after respectively eight and two years of background treatment with hydroxychloroquine 400mg/day. This result is lower than that of Hickman in the United Kingdom [11]. Several other authors in the literature have reported similar results with other molecules [12-15]. These results could be explained by the mechanism of action of these different molecules: hydroxychloroquine [6], cyclophosphamide [16], rituximab [17,18]. Disease activity over one year of followup, there was a significant decrease in SELENA SLEDAI scores from an average of 9.07 at the first appointment of the year to 4.62 at the last appointment, (p=0.001). The majority of patients had mild disease activity at the end of 2020. Our results were comparable to those of Shariati-Sarabi (p<0.001)[6], and Dario Roccatello also found an improvement in SLEDAI score from a mean of 17.3 before treatment to 3.1 after one year of rituximab and cyclophosphamide therapy [13]. Clinical remission was observed in 16 patients. This result could be explained by an effective choice of treatment by the physician, best suited to the clinical picture, as well as good compliance by the patient.

CONCLUSION

At the end of our study, we noted an evolution under treatment, marked by an improvement on the clinical level and a response on the immunological level.

REFERENCES

1. Protocole National de Diagnostic et de Soins. Lupus systémique. Paris : Filière FAI2R. 2020; 1-89.

2. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the eular standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008; 67:195-205.

3. Seror R. Évaluation thérapeutique dans le lupus érythémateuxsystémique. In : Lupus érythémateux. 1re éd. Strasbourg : Elsevier Masson. 2013; 209-21.

4. Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine. ACR Open Rheumatol. 2019; 1: 593-599.

5. Diop MM, Guèye YA, Leye A, Touré PS, Berthe A, Ka MM. Les modes de révélation du lupus érythémateux systémique à Dakar (Sénégal): à propos d’une série de 161 cas. Rev Afr Med Int. 2014; 1:12-15.

6. Shariati-Sarabi Z, Tavakol Afshari J, Mahmoudi M, Dormanesh B, Jahandoost F, Khoshdel Ar, et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacol. 2018; 26: 1175- 1182.

7. Meyer O. Lupus érythémateux systémique. EMC - Rhum Orthop. 2005; 2: 1-32.

8. Zomalheto Z, Assogba M, Agbodande A, Atadokpede F, Gounongbe M, Avimadje M. Lupus érythémateux systémique : particularités au Bénin et en Afrique de l’Ouest. Tunis Med. 2014; 92: 707-710.

9. Toumin C, Mamady D, Mamoudou C, Michel K, Bakari T, Lamine K, et al. Présentation clinique, traitement et évolution du lupus systémique au CHU de Treichville à Abidjan. Health Sci Dis. 2021; 22: 88-91.

10. Gheita TA, Abaza NM, Hammam N, Mohamed AA, El-Gazzar II, Eissa AH. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies. Lupus. 2018; 27:1081- 1087.

11. Hickman RA, Hira-Kazal R, Yee CS, Toescu V, Gordon C. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol. 2015; 34: 263-271.

12. Tew GW, Rabbee N, Wolslegel K, Hsieh H-J, Monroe JG, Behrens TW, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010; 19: 146- 157.

13. Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant. 2011; 26: 3987-3992.

14. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide : clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008; 67: 330-334.

15. Aguiar R, Araújo C, Martins-Coelho G, Isenberg D. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years. Arthritis Care Res. 2017; 69: 257-262.

16. Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017; 16: 411-419.

17. Terrier B, Mouthon L. Lupus érythémateux systémique - traitements par anticorps monoclonaux et molécules recombinantes. Med Sci (Paris). 2013; 29: 65-73.

18. Lekpa FK, Marini A, Claudepierre P, Chevalier X. Intérêt du rituximab dans le traitement du lupus érythémateux systémique. Lettre Rhumatol. 2008; 340: 12-14.

YAMEOGO NW, ZABSONRE/TIENDREBEOGO WJS, TINNI IA, SAWADOGO S, KABORE F, et al. (2022) Therapeutic Response of Patients followed for Systemic Lupus Erythematosus in the Rheumatology Department of the University Hospital of Bogodogo. Ann Orthop Rheumatol 9(1): 1098.

Received : 26 Apr 2022
Accepted : 25 May 2022
Published : 28 May 2022
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X